Abstract: Synthetic disaccharide hydrocarbons (DSHs) that reactive bacterials swarming motility and inhibit bacterial adhesion and biofilm formation. A library of DSHs were tested in several experiment for the impact on various Pseudomonas aeruginosa populations and compared against existing compounds to determine efficacy and utility. Certain DSHs were also to determine the ability to clear bacteria in a mouse pneumonia model.

Abstract: Synthetic disaccharide hydrocarbons (DSHs) that reactive bacterials swarming motility and inhibit bacterial adhesion and biofilm formation. A library of DSHs were tested in several experiment for the impact on various Pseudomonas aeruginosa populations and compared against existing compounds to determine efficacy and utility. Certain DSHs were also to determine the ability to clear bacteria in a mouse pneumonia model.

Abstract: Synthetic disaccharide hydrocarbons (DSHs) that reactive bacterials swarming motility and inhibit bacterial adhesion and biofilm formation. A library of DSHs were tested in several experiment for the impact on various Pseudomonas aeruginosa populations and compared against existing compounds to determine efficacy and utility. Certain DSHs were also to determine the ability to clear bacteria in a mouse pneumonia model.

Abstract: Disclosed in certain embodiments is a compound of Formula I: X—Z?? (I) wherein X is a monosugar or disugar moiety and Z is a C8-20 straight chain alkyl, alkenyl or alkynyl having 1-5 substituents (Y) on the first 6 carbons proximal to the disugar moiety, wherein each Y is independently C1-8 linear alkyl, C3-8 branched alkyl, C3-8 cycloalkyl, halogen, hydroxyl, monocyclic aromatic, monocyclic heteroaromatic, bicyclic aromatic, bicyclic heteroaromatic, tricyclic aromatic, or tricyclic heteroaromatic, wherein each Y is independently optionally substituted with C1-8 linear alkyl, C3-8 branched alkyl, C3-8 cycloalkyl, halogen or hydroxyl and pharmaceutical compositions and methods thereof.

Abstract: Synthetic disaccharide hydrocarbons (DSHs) that reactive bacterials swarming motility and inhibit bacterial adhesion and biofilm formation. A library of DSHs were tested in several experiment for the impact on various Pseudomonas aeruginosa populations and compared against existing compounds to determine efficacy and utility. Certain DSHs were also to determine the ability to clear bacteria in a mouse pneumonia model.

Abstract: A porous hydrogel sensor that is responsive to the presence of one or more target compounds in solution is synthesized based on demixing of certain molecules in the presence of a target compound. The porous hydrogel sensor may include fluorescently tagged antibodies that are noncovalently bound to the gel and then released in the presence of the target antigen. The porous hydrogel sensor may alternatively include dissolvable cross-links using polymerized antibody and antigen complexes so that, in the presence of the target antigen, the cross-links will be displaced and the hydrogel will dissolve.

Abstract: The present invention relates to a non-amphiphile-based water-in-water emulsion composition. The non-amphiphile-based water-in-water emulsion composition includes a water-soluble polymer, a non-amphiphilic lyotropic mesogen encapsulated by the water-soluble polymer; and water. In one embodiment, the non-amphiphilic lyotropic mesogen includes, without limitation, a lyotropic chromonic liquid crystal, and more specifically disodium cromoglycate (DSCG). In another embodiment, the water-soluble polymer can include, without limitation, a polyacrylamide, a polyol, a polyvinylpyrrolidone, a polysaccharide, or a water-soluble fluoride-bearing polymer. The present invention also relates to a porous hydrogel made with the use of the non-amphiphile-based water-in-water emulsion. The present invention further relates to using the emulsion and hydrogel for various applications.

Abstract: A library of unnatural squarylated homoserine lactones (SHLs) and squarylated lactones that bear potential to modulate biofilm formation in Gram negative bacteria. At low concentrations (˜200 ?M), these small molecules inhibit biofilm formation of E. coli. Moreover, these compounds are not toxic up to 300 ?M and do not significantly attenuate E. coli growth. The SHLs have potential to disperse established biofilm and demonstrate an enhanced reduction (˜50%) of the maximum biofilm thickness by use of SHLs during biofilm growth.

Abstract: A library of unnatural squarylated homoserine lactones (SHLs) and squarylated lactones that bear potential to modulate biofilm formation in Gram negative bacteria. At low concentrations (˜200 ?M), these small molecules inhibit biofilm formation of E. coli. Moreover, these compounds are not toxic up to 300 ?M and do not significantly attenuate E. coli growth. The SHLs have potential to disperse established biofilm and demonstrate an enhanced reduction (˜50%) of the maximum biofilm thickness by use of SHLs during biofilm growth.

Abstract: A system and method for preventing protein aggregation is developed by covalent modification of proteins with organic molecules that can preserve the native protein folding. Proteins are covalently modified with sugar alcohols or cyclodextrins (organic Kosmotropes) or other small molecule drugs by water-driven bioorganic reactions in water. In the water-driven bioorganic reactions, the reagent is stable in water and can modify lysine residues or cysteine residue of a protein at physiological conditions with high yield and fast rate. Proteins and antibodies will be modified by non-natural sugar alcohols. As a result, the efficacy of protein drugs (reduction in aggregation and enzymatic degradation, and increase in blood stream life time) may be improved.

Abstract: A method for inhibiting the growth of a microorganism using an effective amount of one or more of the following synthetic brominated furanones: (i) 4-bromo-5Z-(bromomethylene)-3-methylfuran-2-one; (ii) 3-(dibromomethyl)-5-(dibromomethylene)furan-2-one; (iii) 3-(bromomethyl)-5-(dibromomethylene)furan-2-one; (iv) 4-bromo-3-(bromomethyl)-5Z-(bromomethylene)furan-2-one; or (v) 4-bromo-5-(dibromomethyl)-3-methylfuran-2(5H)-one. The brominated furanones inhibit the growth of both fungi and bacteria, including the fungal species Candida albicans, Gloeophyllum trabeum, Chaetomium globosum, and Trametes versicolor and the bacterial species Pseudomonas aeruginosa. The brominated furanones can be used topically or internally to treat human infections, and can be used to treat other objects, such as wood building supplies, to prevent fungal rot.

Abstract: A method for inhibiting the growth of a microorganism using an effective amount of one or more of the following synthetic brominated furanones: (i) 4-bromo-5Z-(bromomethylene)-3-methylfuran-2-one; (ii) 3-(dibromomethyl)-5-(dibromomethylene)furan-2-one; (iii) 3-(bromomethyl)-5-(dibromomethylene)furan-2-one; (iv) 4-bromo-3-(bromomethyl)-5Z-(bromomethylene)furan-2-one; or (v) 4-bromo-5-(dibromomethyl)-3-methylfuran-2(5H)-one. The brominated furanones inhibit the growth of both fungi and bacteria, including the fungal species Candida albicans, Gloeophyllum trabeum, Chaetomium globosum, and Trametes versicolor and the bacterial species Pseudomonas aeruginosa. The brominated furanones can be used topically or internally to treat human infections, and can be used to treat other objects, such as wood building supplies, to prevent fungal rot.

Abstract: A method for inhibiting the growth of a microorganism using an effective amount of one or more of the following synthetic brominated furanones: (i) 4-bromo-5Z-(bromomethylene)-3-methylfuran-2-one; (ii) 3-(dibromomethyl)-5-(dibromomethylene)furan-2-one; (iii) 3-(bromomethyl)-5-(dibromomethylene)furan-2-one; (iv) 4-bromo-3-(bromomethyl)-5Z-(bromomethylene)furan-2-one; or (v) 4-bromo-5-(dibromomethyl)-3-methylfuran-2(5H)-one. The brominated furanones inhibit the growth of both fungi and bacteria, including the fungal species Candida albicans, Gloeophyllum trabeum, Chaetomium globosum, and Trametes versicolor and the bacterial species Pseudomonas aeruginosa. The brominated furanones can be used topically or internally to treat human infections, and can be used to treat other objects, such as wood building supplies, to prevent fungal rot.

Abstract: Liquid crystal compositions that exhibit little or no toxicity with respect to cells include liquid crystals with chemical functional groups such as fluorine atoms, fluorophenyl groups, or difluorophenyl groups. Liquid crystals with little or no toxicity to cell lines may be added to cell culture media or added to components used in cell culture media. Cells may be grown in cell culture media that includes liquid crystals that exhibit little or no toxicity to cells.

Abstract: A system and method for using gradient nanotopography to increase mammalian cell attachment and cell confinement on surfaces. A surface platform consisting of a thin film of gold possessing a gradient of topography on the surface and self-assembled monolayers of alkanethiols presenting desired functional groups is formed. A gradient in the chemical properties is induced in the terminal groups of the monolayer because of the continuous increase in the surface area and the anisotropy of gold film structure. The gradient nanotopraphy provides simultaneous control of two key properties, the presentation of the terminal functional groups and a continuous increase in the surface density of functional groups on the surface. This control provides for drug screening assays using adherent cell-based experiments.

Abstract: A system and method for preventing protein aggregation is developed by covalent modification of proteins with organic molecules that can preserve the native protein folding. Proteins are covalently modified with sugar alcohols or cyclodextrins (organic Kosmotropes) or other small molecule drugs by water-driven bioorganic reactions in water. In the water-driven bioorganic reactions, the reagent is stable in water and can modify lysine residues or cysteine residue of a protein at physiological conditions with high yield and fast rate. Proteins and antibodies will be modified by non-natural sugar alcohols. As a result, the efficacy of protein drugs (reduction in aggregation and enzymatic degradation, and increase in blood stream life time) may be improved.

Abstract: A method for inhibiting the growth of a microorganism using an effective amount of one or more of the following synthetic brominated furanones: (i) 4-bromo-5Z-(bromomethylene)-3-methylfuran-2-one; (ii) 3-(dibromomethyl)-5-(dibromomethylene)furan-2-one; (iii) 3-(bromomethyl)-5-(dibromomethylene)furan-2-one; (iv) 4-bromo-3-(bromomethyl)-5Z-(bromomethylene)furan-2-one; or (v) 4-bromo-5-(dibromomethyl)-3-methylfuran-2(5H)-one. The brominated furanones inhibit the growth of both fungi and bacteria, including the fungal species Candida albicans, Gloeophyllum trabeum, Chaetomium globosum, and Trametes versicolor and the bacterial species Pseudomonas aeruginosa. The brominated furanones can be used topically or internally to treat human infections, and can be used to treat other objects, such as wood building supplies, to prevent fungal rot.

Abstract: The present invention relates to a non-amphiphile-based water-in-water emulsion composition. The non-amphiphile-based water-in-water emulsion composition includes a water-soluble polymer, a non-amphiphilic lyotropic mesogen encapsulated by the water-soluble polymer; and water. In one embodiment, the non-amphiphilic lyotropic mesogen includes, without limitation, a lyotropic chromonic liquid crystal, and more specifically disodium cromoglycate (DSCG). In another embodiment, the water-soluble polymer can include, without limitation, a polyacrylamide, a polyol, a polyvinylpyrrolidone, a polysaccharide, or a water-soluble fluoride-bearing polymer. The present invention also relates to a porous hydrogel made with the use of the non-amphiphile-based water-in-water emulsion. The present invention further relates to using the emulsion and hydrogel for various applications.

Abstract: ABSTRACT A system and method for using gradient nanotopography to increase mammalian cell attachment and cell confinement on surfaces. A surface platform consisting of a thin film of gold possessing a gradient of topography on the surface and self-assembled monolayers of alkanethiols presenting desired functional groups is formed. A gradient in the chemical properties is induced in the terminal groups of the monolayer because of the continuous increase in the surface area and the anisotropy of gold film structure. The gradient nanotopraphy provides simultaneous control of two key properties, the presentation of the terminal functional groups and a continuous increase in the surface density of functional groups on the surface. This control provides for drug screening assays using adherent cell-based experiments.

Abstract: Liquid crystal compositions that exhibit little or no toxicity with respect to cells include liquid crystals with chemical functional groups such as fluorine atoms, fluorophenyl groups, or difluorophenyl groups. Liquid crystals with little or no toxicity to cell lines may be added to cell culture media or added to components used in cell culture media. Cells may be grown in cell culture media that includes liquid crystals that exhibit little or no toxicity to cells.